ArticleSubstance use & addiction journal2026
When Agitation Meets Intoxication: A Retrospective Comparison of Intramuscular Olanzapine and Haloperidol Among Patients With and Without Substance Use in a Psychiatric Emergency Service.
Article in Substance use & addiction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical predictors of repeat intramuscular medication administration for acute agitation: A retrospective cohort study.General hospital psychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSubstance use is a major contributor to psychiatric emergencies, often complicating the management of acute agitation. Despite the high prevalence of co-occurring substance use in emergency psychiatric settings, evidence guiding pharmacologic interventions remains limited. This study examined whether active substance use, as measured by urine drug screening (UDS), predicted clinical and safety outcomes among patients requiring intramuscular (IM) medication for agitation in an emergency psychiatric setting.
methodsThis retrospective chart review included 103 patients presenting to a Comprehensive Psychiatric Emergency Program (CPEP) between January 2020 and November 2022 who received IM haloperidol lactate (HL) or IM olanzapine (OL) and completed UDS. Patients with positive (UDS+) screens were compared to those with negative (UDS-) screens on demographic, clinical, and medication-related outcomes. Primary medication outcomes were the need for repeat IM medication administration and time to next administration. Secondary measures included physiologic changes, adverse effects, and restraint/seclusion use.
resultsFifty-eight patients (56.3%) had a positive UDS. The UDS+ group was younger and more frequently had an incarceration history, but did not differ from the UDS- group in terms of diagnoses, hospitalization history, or adverse events. UDS+ patients had a significantly longer time to next medication administration (mean 10.0 vs 6.5 hours,
conclusionsPatients with active substance use exhibited similar or greater responses to standard IM treatment for agitation without increased safety concerns. Findings support potential safety and efficacy of common pharmacologic approaches in this high-risk population, though a modest single-site cohort may limit generalizability. There is a need for prospective, multisite replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.